JP5766775B2 - Method for producing skin external preparation suitable for dullness improvement - Google Patents
Method for producing skin external preparation suitable for dullness improvement Download PDFInfo
- Publication number
- JP5766775B2 JP5766775B2 JP2013247525A JP2013247525A JP5766775B2 JP 5766775 B2 JP5766775 B2 JP 5766775B2 JP 2013247525 A JP2013247525 A JP 2013247525A JP 2013247525 A JP2013247525 A JP 2013247525A JP 5766775 B2 JP5766775 B2 JP 5766775B2
- Authority
- JP
- Japan
- Prior art keywords
- oil
- skin
- external preparation
- extract
- yac compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims description 28
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 35
- 241000196324 Embryophyta Species 0.000 claims description 23
- 229960003180 glutathione Drugs 0.000 claims description 23
- 108010024636 Glutathione Proteins 0.000 claims description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 239000003995 emulsifying agent Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 241001071804 Gentianaceae Species 0.000 claims description 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims description 5
- 238000001228 spectrum Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 241001530209 Swertia Species 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 description 31
- -1 acetonitrile Chemical class 0.000 description 26
- 239000003921 oil Substances 0.000 description 24
- 239000012071 phase Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 229920001296 polysiloxane Polymers 0.000 description 8
- 239000004359 castor oil Substances 0.000 description 7
- 235000019438 castor oil Nutrition 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000006096 absorbing agent Substances 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 239000007764 o/w emulsion Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical compound CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 240000006891 Artemisia vulgaris Species 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 108010055267 advanced glycation end products-bovine serum albumin Proteins 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940031723 1,2-octanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RKJGFHYCZPZJPE-UHFFFAOYSA-N 2,2-bis(16-methylheptadecanoyloxymethyl)butyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C RKJGFHYCZPZJPE-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- NCLNAHJFXIKYBY-UHFFFAOYSA-N 2-hexyldecyl 16-methylheptadecanoate Chemical compound CCCCCCCCC(CCCCCC)COC(=O)CCCCCCCCCCCCCCC(C)C NCLNAHJFXIKYBY-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000153742 Semblis Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- RJDOZRNNYVAULJ-UHFFFAOYSA-L [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] RJDOZRNNYVAULJ-UHFFFAOYSA-L 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- POJOORKDYOPQLS-UHFFFAOYSA-L barium(2+) 5-chloro-2-[(2-hydroxynaphthalen-1-yl)diazenyl]-4-methylbenzenesulfonate Chemical compound [Ba+2].C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O.C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O POJOORKDYOPQLS-UHFFFAOYSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 229940073609 bismuth oxychloride Drugs 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- DBZJJPROPLPMSN-UHFFFAOYSA-N bromoeosin Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 DBZJJPROPLPMSN-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 229910000428 cobalt oxide Inorganic materials 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- FHRUGNCCGSEPPE-UHFFFAOYSA-L disodium;2-(4,5-dibromo-3,6-dioxido-9h-xanthen-9-yl)benzoate;hydron Chemical compound [H+].[Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1C2=CC=C([O-])C(Br)=C2OC2=C(Br)C([O-])=CC=C21 FHRUGNCCGSEPPE-UHFFFAOYSA-L 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- TUKWPCXMNZAXLO-UHFFFAOYSA-N ethyl 2-nonylsulfanyl-4-oxo-1h-pyrimidine-6-carboxylate Chemical compound CCCCCCCCCSC1=NC(=O)C=C(C(=O)OCC)N1 TUKWPCXMNZAXLO-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- TXGJTWACJNYNOJ-UHFFFAOYSA-N hexane-2,4-diol Chemical compound CCC(O)CC(C)O TXGJTWACJNYNOJ-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229940118594 trimethylolpropane triisostearate Drugs 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Description
本発明は、化粧料などの皮膚外用剤に関し、更に詳細には、くすみ改善に有用な化粧料などの皮膚外用剤に関する。 The present invention relates to an external preparation for skin such as cosmetics, and more particularly to an external preparation for skin such as cosmetics useful for improving dullness.
化粧料に於いて、「くすみ対応」は近年重要な課題となっている。従前、くすみはメラニンの蓄積と、その分布様式(メラニンの分布の不均一性)に起因するものである(例えば、特許文献1を参照)、或いは、血行の不順やそれによって生じるヘモグロビン酸素飽和度の低下によるものである(例えば、特許文献2を参照)等の諸説が存するが、その原因については明確ではない。又、明らかな点ではくすみはメラニン産生抑制作用を有する美白剤によって多少の改善はするが、解消はしない等の特性を有し、単一原因によるよりは、複合化した原因背景が存することが推測される。又、この素因によって「くすみ」の一言に包含されている生理現象に於いても多種多様なものが存することが推測される。又、この様なくすみが存することにより、第三者に於ける外観印象において、「疲れている」、「元気がない」、「加齢している」等のネガティブな印象を形成せしめることから、その対応が求められていたが、スキンケアに於いては根本的な解決策が存しないため、メークアップ化粧料による外観印象の改変によって対応されるのが常であった(例えば、特許文献3を参照)。確かに、外観印象の改変による対応手段も重要であるが、スキンケアにより、くすみの存在そのものに対応することも望まれており、この様なスキンケア手段の開発が望まれていた。 In cosmetics, “dullening” has become an important issue in recent years. Conventionally, dullness is caused by accumulation of melanin and its distribution pattern (non-uniform distribution of melanin) (see, for example, Patent Document 1), or irregular blood circulation and hemoglobin oxygen saturation caused thereby. Although there are various theories such as this (for example, see Patent Document 2), the cause is not clear. In addition, it is clear that dullness is improved slightly by a whitening agent having an inhibitory action on melanin production, but it does not disappear, and there is a complex cause background rather than a single cause. Guessed. Also, it is speculated that there are a wide variety of physiological phenomena included in the word “dullness” due to this predisposition. In addition, the presence of such a dullness creates a negative impression such as “I am tired”, “I am not well” or “I am aging” in the appearance impression of a third party. However, since there is no fundamental solution in skin care, it has been usually dealt with by modifying the appearance impression with makeup cosmetics (for example, Patent Document 3). See). Certainly, means for dealing with changes in appearance impression is also important, but it is also desired to deal with the presence of dullness by skin care, and development of such skin care means has been desired.
一方、リンドウ科センブリ属の植物は、開花期の全草を乾燥したものを生薬として民間療法において、腹痛の抑制、消化促進、食欲増進の目的で使用されており、化粧料の分野に於いても、その抽出物を血行促進(例えば、特許文献4を参照)或いは発毛促進(例えば、特許文献5を参照)の目的などで使用されている。しかしながらリンドウ科センブリ属の植物体の抽出物が細胞に於いて、グルタチオンの産生量を増加させる作用を有することは全く知られていない。又、キク科ヨモギの植物体に含有される、次に示す特性を有するYAC化合物及び/又はその塩は、文献未記載の新規化合物であり、当然その薬効についても全く知られていない。更に、これらを組み合わせて皮膚外用剤に含有させることにより、著しいくすみ改善効果を示すことも全く知られていない。
<YAC化合物の特性>
(1)λmaxを405〜415nmと、660〜670nmとに有する。
(2)図1に示す 1 H−NMRスペクトルを有する。
(3)図2に示す 13 C−NMRスペクトルを有する。
(4)以下の条件でのHPLC分析において、15分前後にシングルピークを示す。
移動相:90%アセトニトリル
カラム:ODS4.6×250mm
流速:1ml/min.
温度:40℃
検知:紫外部210nm
(5)化学組成式はC34H40O9であり、質量分析スペクトルは593(M+H)
On the other hand, plants of the genus Gentianaceae are used in folk remedies as herbal medicines, which are dried whole flowers in the flowering period, for the purpose of suppressing abdominal pain, promoting digestion, and increasing appetite. In addition, the extract is used for the purpose of promoting blood circulation (for example, see Patent Document 4) or promoting hair growth (for example, see Patent Document 5). However, it is not known at all that an extract of a plant belonging to the genus Gentianaceae has an action of increasing glutathione production in cells. Moreover, the YAC compound and / or its salt which are contained in the Asteraceae mugwort plant having the following characteristics are novel compounds not described in the literature, and of course, their medicinal effects are not known at all. Furthermore, it is not known at all that a combination of these is incorporated into an external preparation for skin to show a remarkable dullness improving effect.
<Characteristics of YAC compound>
(1) It has (lambda) max in 405-415 nm and 660-670 nm.
(2) 1 H- NMR spectrum shown in FIG.
(3) It has a 13 C- NMR spectrum shown in FIG.
(4) In HPLC analysis under the following conditions, a single peak is shown around 15 minutes.
Mobile phase: 90% acetonitrile column: ODS 4.6 × 250 mm
Flow rate: 1 ml / min.
Temperature: 40 ° C
Detection: UV part 210nm
(5) The chemical composition formula is C 34 H 40 O 9 and the mass spectrometry spectrum is 593 (M + H).
観点を変えて、皮膚老化現象においては、アドバンスド・グリケーション・エンドプロダクツ(以下、AGEsと略することもある)が重要な役割を担っており、これを分解する成分としてはオリーブの葉の抽出物、ヨモギの葉の抽出物などが存することが知られている(例えば、特許文献6、特許文献7、特許文献8を参照)。しかし、AGEs分解剤とリンドウ科センブリ属の植物の抽出物とを組み合わせる技術も、全く開示も示唆も存し
ない。ヨモギの抽出物とセンブリ属の植物の抽出物とを組み合わせて化粧料に含有させることは、その可能性については開示されている(例えば、特許文献9を参照)が、実際の組み合わせての配合は全く為されていない。
From a different perspective, advanced glycation end products (hereinafter sometimes abbreviated as AGEs) play an important role in the skin aging phenomenon. It is known that there is a product, a mugwort leaf extract, etc. (see, for example, Patent Document 6, Patent Document 7, and Patent Document 8). However, there is no disclosure or suggestion of a technique for combining an AGEs degrading agent with an extract of a plant belonging to the genus Gentianaceae. The possibility of combining the extract of mugwort and the extract of the plant of the genus genus in the cosmetic is disclosed for its possibility (see, for example, Patent Document 9), but the combination of the actual combination Is not done at all.
本発明は、この様な状況下為されたものであり、スキンケアにより、くすみの存在そのものに対応する手段を提供することを課題とする。 The present invention has been made under such circumstances, and an object of the present invention is to provide means corresponding to the presence of dullness by skin care.
この様な状況に鑑みて、本発明者らは、スキンケアにより、くすみの存在そのものに対応する手段を求めて、鋭意研究努力を重ねた結果、1)リンドウ科センブリ属の植物体の抽出物と、2)次に示す特性を有するYAC化合物及び/又はその塩とを含有する、皮膚外用剤がその様な作用を有していることを見出し、発明を完成させるに至った。
<YAC化合物の特性>
(1)λmaxを405〜415nmと、660〜670nmとに有する。
(2)図1に示す 1 H−NMRスペクトルを有する。
(3)図2に示す 13 C−NMRスペクトルを有する。
(4)以下の条件でのHPLC分析において、15分前後にシングルピークを示す。
移動相:90%アセトニトリル
カラム:ODS4.6×250mm
流速:1ml/min.
温度:40℃
検知:紫外部210nm
即ち、本発明は以下に示すとおりである。
<1>1)リンドウ科センブリ属の植物体の抽出物と、2)次に示す特性を有するYAC化合物及び/又はその塩とを含有することを特徴とする、皮膚外用剤。
<YAC化合物の特性>
(1)λmaxを405〜415nmと、660〜670nmとに有する。
(2)図1に示す 1 H−NMRスペクトルを有する。
(3)図2に示す 13 C−NMRスペクトルを有する。
(4)以下の条件でのHPLC分析において、15分前後にシングルピークを示す。
移動相:90%アセトニトリル
カラム:ODS4.6×250mm
流速:1ml/min.
温度:40℃
検知:紫外部210nm
(5)化学組成式はC34H40O9であり、質量分析スペクトルは593(M+H)
<2>リンドウ科センブリ属の植物体の抽出物は、該抽出物の20μg/mLの濃度での存在下、ヒト肝ガン由来細胞株HepG2を培養した場合において、非存在下に比して、グルタチオンの産生量を少なくとも40%増加させる作用を有することを特徴とする、<1>に記載の皮膚外用剤。
<3>複合乳化剤形であることを特徴とする、<1>又は<2>に記載の皮膚外用剤。
<4>前記複合乳化剤形は、水相を連続相とし、該連続相中に油滴及び油中水乳化滴が分散した形態の剤形であることを特徴とする、<3>に記載の皮膚外用剤。
<5>1)リンドウ科センブリ属の植物体の抽出物と、2)次に示す特性を有するYAC化合物及び/又はその塩とを、ともに水相中に分散した油中水乳化滴の油相中に含有することを特徴とする、<4>に記載の皮膚外用剤。
In view of such a situation, the present inventors have sought for means corresponding to the presence of dullness by skin care, and as a result of intensive research efforts, 1) an extract of a plant belonging to the genus Gentianaceae and 2) It has been found that an external preparation for skin containing a YAC compound having the following characteristics and / or a salt thereof has such an action, and has completed the invention.
<Characteristics of YAC compound>
(1) It has (lambda) max in 405-415 nm and 660-670 nm.
(2) 1 H- NMR spectrum shown in FIG.
(3) It has a 13 C- NMR spectrum shown in FIG.
(4) In HPLC analysis under the following conditions, a single peak is shown around 15 minutes.
Mobile phase: 90% acetonitrile column: ODS 4.6 × 250 mm
Flow rate: 1 ml / min.
Temperature: 40 ° C
Detection: UV part 210nm
That is, the present invention is as follows.
<1> An external preparation for skin, comprising 1) an extract of a plant belonging to the genus Gentianaceae and 2) a YAC compound and / or a salt thereof having the following characteristics.
<Characteristics of YAC compound>
(1) It has (lambda) max in 405-415 nm and 660-670 nm.
(2) 1 H- NMR spectrum shown in FIG.
(3) It has a 13 C- NMR spectrum shown in FIG.
(4) In HPLC analysis under the following conditions, a single peak is shown around 15 minutes.
Mobile phase: 90% acetonitrile column: ODS 4.6 × 250 mm
Flow rate: 1 ml / min.
Temperature: 40 ° C
Detection: UV part 210nm
(5) The chemical composition formula is C 34 H 40 O 9 and the mass spectrometry spectrum is 593 (M + H).
<2> An extract of a plant belonging to the genus Gentianaceae, when the human liver cancer-derived cell line HepG2 is cultured in the presence of the extract at a concentration of 20 μg / mL, compared to the absence thereof , The external preparation for skin according to <1>, which has an action of increasing the production amount of glutathione by at least 40% .
<3> The external preparation for skin according to <1> or <2>, which is a complex emulsifier type.
<4> The composite emulsifier form is a dosage form in which an aqueous phase is a continuous phase and oil droplets and water-in-oil emulsified droplets are dispersed in the continuous phase. Skin external preparation.
<5> 1) Oil phase of water-in-oil emulsified droplets in which an extract of a plant belonging to the genus Gentianaceae and 2) a YAC compound and / or a salt thereof having the following characteristics are dispersed in an aqueous phase. The external preparation for skin according to <4>, characterized in that it is contained therein.
本発明によれば、スキンケアにより、くすみの存在そのものに対応する手段を提供することができる。 According to the present invention, means corresponding to the presence of dullness itself can be provided by skin care.
<1>本発明の皮膚外用剤の必須成分であるセンブリの抽出物
本発明の皮膚外用剤は、リンドウ科センブリ属の植物の抽出物を必須成分として含有することを特徴とする。リンドウ科センブリ属の植物としては、センブリ乃至はムラサキセンブリが好ましく例示できる。かかる植物体より抽出物を作成するには、乾燥、細切、粉砕などの加工を施した植物体に、1〜50質量倍の溶媒を加え、所望により攪拌、ホモジネートなど抽出促進措置を加え、室温であれば数日間、沸点付近の温度であれば数時間浸漬し、必要に応じて、濾過などで不溶物を取り除き、減圧留去、凍結乾燥などを行って、適宜分画、精製などを加えて、皮膚外用剤に含有させることが出来る。使用する植物体の部位としては全草が好ましく、植物体の採取時期としては開花期が好ましい。この時、皮膚外用剤に含有させることが出来るか否かの指標としては、ヒト肝ガン由来細胞株HepG2に対して、グルタチオンの産生を促進させることが出来るか否かを用いることが出来る。即ち、以下の手順でグルタチオンの産生に対する作用を計測し、産生の促進値(検体の存在下のグルタチオンの産生量/検体非存在下のグルタチオンの産生量)が1.4以上であった場合には、含有させることが可能であると判別し、1.5以上の場合はより好ましいと判別する。本発明の皮膚外用剤では、かかる含有に適すると判別されたセンブリ属の植物の抽出物を、好ましくは、0.001〜1質量%、より好ましくは、0.01〜0.1質量%含有する。かかるグルタチオンの産生促進が、後記のYAC化合物とともに働いて、くすみの改善を促す。
<1> Extract of assembly which is an essential component of the external preparation for skin of the present invention The external preparation for skin of the present invention is characterized by containing an extract of a plant belonging to the genus Gentianaceae as an essential component. Preferred examples of the plant belonging to the genus Gentianaceae include assembly or murrex. To create an extract from such a plant, add 1 to 50 mass times of solvent to the plant subjected to processing such as drying, shredding, pulverization, etc., and if necessary, add extraction promotion measures such as stirring, homogenate, Soak for several days at room temperature, or for several hours at temperatures near the boiling point, remove insolubles by filtration, etc., if necessary, perform vacuum distillation, freeze drying, etc. In addition, it can be contained in a skin external preparation. The whole plant is preferably used as the plant part to be used, and the flowering period is preferred as the plant collection period. At this time, as an index of whether or not it can be contained in an external preparation for skin, it can be used whether or not the production of glutathione can be promoted with respect to the human liver cancer-derived cell line HepG2. That is, when the effect on the production of glutathione is measured according to the following procedure and the production promotion value (the amount of glutathione produced in the presence of the sample / the amount of glutathione produced in the absence of the sample) is 1.4 or more Is determined to be contained, and when it is 1.5 or more, it is determined that it is more preferable. In the external preparation for skin of the present invention, an extract of a plant belonging to the genus Sembli determined to be suitable for such inclusion is preferably contained in an amount of 0.001 to 1% by mass, more preferably 0.01 to 0.1% by mass. To do. Such production promotion of glutathione works with a YAC compound described later to promote improvement of dullness.
<手技>
ヒト肝ガン由来細胞株HepG2(ATCC;CRL-11997)を用いてグルタチオン産生量の測定試験を実施した。10容量%牛胎児血清(GIBCO社製)含有RPMI1640培地(GIBCO社製)に細胞を懸濁し、培養プレートに播種し、CO 2 インキュベーター(95容量%空気、5容量%二酸化炭素)内、37℃の条件下で24時間培養した。24時間培養後、ジメチルスルホキシドにて懸濁した各抽出物を乾燥固形物量として培地中に20μg/mlの濃度で含む試料添加培地に交換し、さらに24時間培養した。
細胞を回収し、その後−30℃で凍結、融解することで細胞を破砕し、細胞内のグルタチオンを溶出させた。1000xgで15分間、20℃で遠心し、上清を測定試料とした。GSH/GSSG−412キット(OXISResearch社製)を用いて、DTNB法により、グルタチオン量を測定した。即ち、グルタチオン標準品、ブランク、測定試料200μLを、各々のキュベットへ入れ、キット付属のクロモジェン200μLと酵素液200μLを各キュベットに加え、室温で5分間インキュベートした。その後各キュベットにキット付属のNADPH液200μLを添加し、412nmの吸光度の変化を3分間測定した。グルタチオン量は、同時に設定したグルタチオン標準品にて作成した検量線から計算した。
<Procedure>
A measurement test of glutathione production was performed using a human liver cancer-derived cell line HepG2 (ATCC; CRL-11997). Cells were suspended in RPMI 1640 medium (GIBCO) containing 10% by volume fetal calf serum (GIBCO), seeded on a culture plate, and 37 ° C in a CO 2 incubator (95% by volume air, 5% by volume carbon dioxide). The cells were cultured for 24 hours under the above conditions. After culturing for 24 hours, each extract suspended in dimethyl sulfoxide was replaced with a sample-added medium containing 20 μg / ml in the medium as a dry solid amount, and further cultured for 24 hours.
The cells were collected and then frozen and thawed at −30 ° C. to disrupt the cells and elute intracellular glutathione. The sample was centrifuged at 1000 × g for 15 minutes at 20 ° C., and the supernatant was used as a measurement sample. The amount of glutathione was measured by the DTNB method using a GSH / GSSG-412 kit (manufactured by OXIS Research). That is, 200 μL of glutathione standard, blank, and measurement sample were placed in each cuvette, 200 μL of chromogen and 200 μL of enzyme solution included in the kit were added to each cuvette, and incubated at room temperature for 5 minutes. Thereafter, 200 μL of NADPH solution attached to the kit was added to each cuvette, and the change in absorbance at 412 nm was measured for 3 minutes. The amount of glutathione was calculated from a calibration curve prepared with a glutathione standard set at the same time.
<製造例>
リンドウ科センブリ属センブリを開花期に採取し、全草を乾燥後、ミキサーで細切し、100gを秤取った。これに50%エタノール水溶液500mLを加え、5分間超音波処理し、遠心分離(3000rpm;5分)を行い、上清を濾過し、減圧留去した後、水100mLと酢酸エチル100mLを加え、液液抽出を行い、酢酸エチル相を取り、減圧留去し、センブリ抽出物1を得た。このもののグルタチオン産生の促進値(検体の存在下のグルタチオンの産生量/検体非存在下のグルタチオンの産生量)は、1.69± 0.3
4であった。尚、水相を減圧留去したセンブリ抽出物2のグルタチオン産生の促進値(検体の存在下のグルタチオンの産生量/検体非存在下のグルタチオンの産生量)は、1.45±0.48であった。
<Production example>
Gentian family genus assembly was collected at the flowering stage, and the whole plant was dried, then chopped with a mixer, and 100 g was weighed. To this was added 500 mL of 50% ethanol aqueous solution, sonicated for 5 minutes, centrifuged (3000 rpm; 5 minutes), the supernatant was filtered and evaporated under reduced pressure, and then 100 mL of water and 100 mL of ethyl acetate were added. Liquid extraction was performed, and the ethyl acetate phase was taken and distilled off under reduced pressure to obtain
4. In addition, the acceleration value of glutathione production of the
<2>本発明の化粧料の必須成分であるYAC化合物
本発明の化粧料の必須成分であるYAC化合物は次に示す性状を有することを特徴とする。
(性状)
(1)λmaxを405〜415nmと、660〜670nmとに有する。
(2)図1に示す 1 H−NMRスペクトルを有する。
(3)図2に示す 13 C−NMRスペクトルを有する。
(4)以下の条件でのHPLC分析において、15分前後にシングルピークを示す。
(5)化学組成式はC34H40O9であり、質量分析スペクトルは593(M+H)
本発明の化粧料の必須成分であるYAC化合物の紫外・可視吸収スペクトルは図4に示す。この図より、405〜415nmと、660〜670nmとにλmaxが存する特徴が明確に判別できる。本発明の化粧料の必須成分であるこの化合物を特定する場合、かかる紫外・可視部吸収特性は非常に有利である。即ち、多波長の検出器を備えたHPLCを用いて、210nmの吸収で分析し、ピークについて405〜415nmと、660〜670nmとの吸収を確認し、同様に強い吸収が認められた場合には、本願発明のYAC化合物である蓋然性が非常に高い。この意味で有力な確認手段となる。本願発明のYAC化合物は、極性溶媒抽出物の非極性部分に存在する。この為、溶媒で抽出し、抽出溶媒を減圧濃縮などで除去した後に酢酸エチルと水で分液し、酢酸エチル相を採取することにより、濃縮することが出来る。このものをシリカゲルカラムクロマトグラフィーなどを用いて、クロロホルム/メタノール混液系で分画精製することにより単離することが出来る。単離したかどうかについては、以下の条件のHPLC分析でシングルピーク(リテンションタイム15分前後)であるか否かを判別することにより特定することが出来る。図3に分析例を示す。この場合のリテンションタイムは14.7分である。
(HPLC条件)
移動相:90%アセトニトリル
カラム:ODS4.6×250mm
流速:1ml/min.
温度:40℃
検知:紫外部210nm
<2> YAC compound which is an essential component of the cosmetic of the present invention The YAC compound which is an essential component of the cosmetic of the present invention has the following properties.
(Properties)
(1) It has (lambda) max in 405-415 nm and 660-670 nm.
(2) 1 H- NMR spectrum shown in FIG.
(3) It has a 13 C- NMR spectrum shown in FIG.
(4) In HPLC analysis under the following conditions, a single peak is shown around 15 minutes.
(5) The chemical composition formula is C 34 H 40 O 9 and the mass spectrometry spectrum is 593 (M + H).
The ultraviolet / visible absorption spectrum of the YAC compound which is an essential component of the cosmetic of the present invention is shown in FIG . From this figure, it is possible to clearly discriminate the feature that λmax exists at 405 to 415 nm and 660 to 670 nm. When specifying this compound, which is an essential component of the cosmetic of the present invention, such ultraviolet / visible absorption characteristics are very advantageous. That is, using HPLC equipped with a multi-wavelength detector, analysis was performed at 210 nm absorption, and the absorption at 405 to 415 nm and 660 to 670 nm was confirmed for the peak. The probability of being the YAC compound of the present invention is very high. In this sense, it is an effective confirmation means. The YAC compound of the present invention is present in the nonpolar part of the polar solvent extract. For this reason, it can be concentrated by extracting with a solvent, removing the extraction solvent by concentration under reduced pressure, etc., then separating with ethyl acetate and water, and collecting the ethyl acetate phase. This can be isolated by subjecting it to fractional purification in a chloroform / methanol mixture system using silica gel column chromatography or the like. Whether or not it is isolated can be identified by determining whether or not it is a single peak (retention time around 15 minutes) by HPLC analysis under the following conditions. FIG. 3 shows an analysis example. In this case, the retention time is 14.7 minutes.
(HPLC conditions)
Mobile phase: 90% acetonitrile column: ODS 4.6 × 250 mm
Flow rate: 1 ml / min.
Temperature: 40 ° C
Detection: UV part 210nm
かかる本発明の化粧料の必須成分であるYAC化合物は、キク科ヨモギ乃至はキク科カワラヨモギの植物体を極性溶媒、例えば、含水していても良い有機溶媒、例えば、メタノール、エタノール、イソプロピルアルコール、n−ブタノール、プロピレングリコール、1,3−ブタンジオールなどのアルコール類、アセトン、メチルエチルケトンなどのケトン類、ジエチルエーテル、イソプロピルエーテル、テトラヒドロフランなどのエーテル類、クロロホルム、ジクロロメタンなどのハロゲン化炭化水素、酢酸エチル、蟻酸メチルなどのカルボン酸エステル類、アセトニトリルなどのニトリル類などで抽出することにより、前記YAC化合物を含む抽出物を得ることが出来、これを前記の如く、液液抽出やカラムクロマトグラフィーなどの精製手段により単離精製することが出来る。抽出溶媒としては、含水アルコールが特に好ましく、70〜90%エタノール水溶液を用いることが特に好ましい。抽出に用いる植物体の部位は、地上部を用いることが好ましい。植物体は、抽出に先立って、細切乃至は乾燥して粉砕するなど、細片化処置を行うことが好ましい。抽出は、室温であれば数日間、沸点付近の温度であれば数時間植物体乃至はその加工物を溶媒に浸漬することにより為しうる。 The YAC compound which is an essential component of the cosmetic of the present invention is a polar solvent, for example, an organic solvent which may contain water, such as methanol, ethanol, isopropyl alcohol, Alcohols such as n-butanol, propylene glycol and 1,3-butanediol, ketones such as acetone and methyl ethyl ketone, ethers such as diethyl ether, isopropyl ether and tetrahydrofuran, halogenated hydrocarbons such as chloroform and dichloromethane, ethyl acetate By extracting with carboxylic acid esters such as methyl formate and nitriles such as acetonitrile, an extract containing the YAC compound can be obtained. As described above, this can be used for liquid-liquid extraction or column chromatography. Spirit It can be isolated and purified by means. As the extraction solvent, a hydrous alcohol is particularly preferred, and a 70 to 90% aqueous ethanol solution is particularly preferred. It is preferable to use the above-ground part for the plant part used for extraction. Prior to extraction, the plant body is preferably subjected to a fragmentation treatment such as chopping or drying and crushing. The extraction can be performed by immersing the plant or the processed product in a solvent for several days at room temperature and for several hours at a temperature near the boiling point.
斯くして得られたYAC化合物は、シリカゲルを担体とする薄層クロマトグラフィー(展開液、クロロホルム:メタノール=95:5〜8:2)においてシングルスポットを呈し、AGEs分解活性を示す。AGEs分解活性は、簡易的にはα−ジケトンの切断活性の強さを指標とし、定量化することが出来る。即ち、1−フェニル−1,2−プロパンジオンとともにインキュベートし、切断によって生じる安息香酸を吸光度で定量し、安息香酸の生成量が多いほどAGEs分解能が高いと判別できる。これよりvivoに近い評価としては、実際にグルコースと牛血清アルブミンとをインキュベートして作成したAGEsを分解せしめ、分解量を定量し、かかる分解量を指標にAGEs分解能を定量する方法も存する。本発明の化粧料の必須成分であるYAC化合物はこの様な方法でAGEs分解
能を定量した場合、α−ジケトンの分解において40〜60%程度の分解率を呈し、牛アルブミンAGEsに対しては、10 -3 質量%で65〜80%程度の分解率を呈する。この性質を利用して本発明の化粧料の必須成分であるYAC化合物はAGEs分解剤として化粧料等に配合し、光照射などで生じたAGEsを速やかに分解し、この蓄積を防ぐことが出来る。以下に、これらの評価方法の手順を示す。本発明の化粧料に於いては、かかるAGEs分解作用がくすみ改善、特にメラニン産生抑制剤で改善しにくいくすみの改善に有用であると考えられる。本発明の化粧料に於いてはかかるAGEs分解作用を明確に発現するドーズでのYAC化合物の含有が好ましい。具体的には、10 -4 〜10 -2 質量%含有させることが特に好ましい。
The YAC compound thus obtained exhibits a single spot in thin-layer chromatography (developing solution, chloroform: methanol = 95: 5 to 8: 2) using silica gel as a carrier, and exhibits AGE decomposition activity. The AGEs degradation activity can be quantified simply using the strength of the cleavage activity of α-diketone as an index. That is, it is incubated with 1-phenyl-1,2-propanedione, benzoic acid generated by cleavage is quantified by absorbance, and it can be determined that the greater the amount of benzoic acid produced, the higher the AGEs resolution. As an evaluation closer to vivo, there is a method in which AGEs prepared by actually incubating glucose and bovine serum albumin are decomposed, the amount of decomposition is quantified, and the AGEs resolution is quantified using the amount of decomposition as an index. The YAC compound, which is an essential component of the cosmetic composition of the present invention, exhibits a degradation rate of about 40 to 60% in the degradation of α-diketones when AGEs resolution is quantified by such a method. For bovine albumin AGEs, It exhibits a decomposition rate of about 65 to 80% at 10 −3 mass%. Utilizing this property, the YAC compound, which is an essential component of the cosmetic of the present invention, can be blended in cosmetics and the like as an AGEs decomposing agent to quickly decompose AGEs generated by light irradiation and prevent this accumulation. . The procedure of these evaluation methods is shown below. In the cosmetic of the present invention, it is considered that such AGE decomposition action is useful for improving dullness, particularly for improving dullness that is difficult to improve with a melanin production inhibitor. In the cosmetic of the present invention, it is preferable that the YAC compound is contained in a dose that clearly expresses the AGE decomposition action. Specifically, it is particularly preferable to contain 10 −4 to 10 −2 mass%.
<α−ジケトンのC−C結合切断能の測定>
22mM 1−phenyl−1,2−propanedion/MeOH+0.1Mリ
ン酸緩衝液(PH7.4)1mlと、測定用試料1mlを混合し、37℃で10時間反応させ、安息香酸の量をHPLCにて定量する。
(HPLC条件)
・分析条件 検出器 :紫外吸光光度計(測定波長:260nm)
・カラム :東ソー TSK−ODS80TsQA カラム温度:室温
・移動層 :氷酢酸2g/アセトニトリル500ml+エデト酸二ナトリウム溶液(1→
250)500ml 流量:1ml/min
<Measurement of CC bond cleavage ability of α-diketone>
1 ml of 22 mM 1-phenyl-1,2-propanedion / MeOH + 0.1 M phosphate buffer (PH7.4) and 1 ml of measurement sample were mixed and reacted at 37 ° C. for 10 hours. The amount of benzoic acid was determined by HPLC. Quantify.
(HPLC conditions)
・ Analysis conditions Detector: Ultraviolet absorptiometer (measurement wavelength: 260 nm)
-Column: Tosoh TSK-ODS80TsQA Column temperature: Room temperature-Moving layer: Glacial acetic acid 2 g /
250) 500 ml Flow rate: 1 ml / min
<グルコース−牛血清アルブミンAGEs分解能の測定>
用いる材料は以下の通り。
AGE−BSA:グルコースとBSAを37℃で12週間以上インキュベートし、
PD−10 columns(Amersham Biosciences 17−085
1−01)にて余分なglucoseを除いたもの
1次抗体 :Anti−Albumin,Bovine Serum,Rabbit−Poly ROCKLAND 201−41331/20000
2次抗体 :Goat anti−rabbitIGg horseradish
peroxidase conjugate Bio RAD 170−6515 1/10
000
基質 :TMB solution Wako 546−01911
(手順)
typeIコラーゲンコートした96穴マイクロプレート(Bio Coat 35 44
07)に10μg/mlのAGE−BSAを100μl加え、(1.0μgAGE−BSA/well) 37℃にて4時間静置した後、0.05%Tween20/PBS(−
)にて3回洗浄(マイクロミキサー上で室温・3分間振とう)し、PBS(−)に溶解した各濃度の試料を100μlを加え、37℃で10時間以上反応させる。その後、0.05%Tween20/PBS(−)にて3回洗浄し、1次抗体を各wellに100μl/well加え、室温で30分間静置する。0.05%Tween20/PBS(−)にて3回洗浄し、2次抗体を100μl/well入れ、室温30分間静置する。0.05%Tween20/PBS(−)にて3回洗浄し、TMBを100μl/well加え、室温15分反応させる。1N HClを100μl/well入れ、反応を止め、450
nmの吸光度を測定する。AGEsの量を変え、検量線を引き、この検量線より残存AGEs量を定量した。残存AGEsを添加したAGEsより減じ、添加したAGEsで除し、100を乗じてAGEs分解率を算出した。
<Measurement of glucose-bovine serum albumin AGE resolution>
The materials used are as follows.
AGE-BSA: Glucose and BSA are incubated at 37 ° C. for 12 weeks or more,
PD-10 columns (Amersham Biosciences 17-085
1-01) Excluding excess glucose Primary antibody: Anti-Albumin, Bovine Serum, Rabbit-Poly ROCKLAND 201-41331 / 20000
Secondary antibody: Goat anti-rabbit IG ghorseradish
peroxidase conjugate Bio RAD 170-6515 1/10
000
Substrate: TMB solution Wako 546-01911
(procedure)
96-well microplate coated with type I collagen (Bio Coat 35 44
07) was added 100 μl of 10 μg / ml AGE-BSA and (1.0 μg AGE-BSA / well) was allowed to stand at 37 ° C. for 4 hours, and then 0.05% Tween20 / PBS (−
) 3 times (shaking on a micromixer at room temperature for 3 minutes), adding 100 μl of each concentration sample dissolved in PBS (−), and allowing to react at 37 ° C. for 10 hours or more. Then, it wash | cleans 3 times by 0.05% Tween20 / PBS (-), 100 microliters / well of primary antibodies are added to each well, and it leaves still for 30 minutes at room temperature.
Measure the absorbance at nm. The amount of AGEs was changed, a calibration curve was drawn, and the amount of residual AGEs was quantified from this calibration curve. The AGEs decomposition rate was calculated by subtracting the remaining AGEs from the added AGEs, dividing by the added AGEs, and multiplying by 100.
本発明の化粧料の必須成分であるYAC化合物は、図1、図2のNMRデータより、水酸基、カルボキシル基等の反応性置換基を有すると考えられ、かかる反応性基を利用して誘導体へと導くことが出来る。かかる誘導体が本発明の化粧料の必須成分であるYAC化合物の誘導体である。本発明の誘導体としては、例えば、メチルアイオダイドなどのハロゲン化炭化水素を用いてアルキル化したアルキルエーテル体、アルキルエステル体、アシルハライドを反応させて得られるアシル化体、モノエタノールアミンなどを反応させたアミド体などが好適に例示できる。前記の評価法においてAGEs分解能を有する限り、これらの誘導体は本発明の化粧料の必須成分として、本発明の技術的範囲に属する。 The YAC compound, which is an essential component of the cosmetic of the present invention, is considered to have a reactive substituent such as a hydroxyl group or a carboxyl group from the NMR data in FIGS. 1 and 2, and is converted to a derivative using such a reactive group. Can be led. Such a derivative is a derivative of a YAC compound that is an essential component of the cosmetic of the present invention. Examples of the derivatives of the present invention include reacting alkyl ethers, alkyl esters, acylated products obtained by reacting acyl halides, monoethanolamine, etc., alkylated with a halogenated hydrocarbon such as methyl iodide. Preferred examples include amides that have been prepared. As long as it has AGEs resolution in the above evaluation method, these derivatives belong to the technical scope of the present invention as essential components of the cosmetic of the present invention.
<3>本発明の皮膚外用剤
本発明の皮膚外用剤は、前記必須成分を含有し、乳化剤形であることを特徴とする。前記乳化剤形としては、水中油乳化剤形、油中水乳化剤形、複合乳化剤形の何れもが適用可能であり、特に複合乳化剤形が好ましい。複合乳化剤形には、油中水中油剤形や水中油中水剤形のように、エマルションの分散している滴の構造自身が複合化しているタイプ(分散滴複合タイプ)と、連続相は油相なり、水相なりの一相であり、分散滴が油滴、油中水滴分散或いは水滴、水中油滴分散などのように分散滴が多様化しているタイプ(分散滴多様化タイプ)とが存し、本発明の皮膚外用剤では、分散滴多様化タイプが特に好ましい。
<3> External preparation for skin of the present invention The external preparation for skin of the present invention contains the essential components and is in the form of an emulsifier. As the emulsifier form, any of an oil-in-water emulsifier form, a water-in-oil emulsifier form, and a composite emulsifier form can be applied, and a composite emulsifier form is particularly preferable. There are two types of complex emulsifier types: the oil-in-water-in-oil form and the water-in-oil-in-water form, in which the structure of the dispersed droplets of the emulsion itself is complex (dispersed droplet complex type), A phase that is a phase, a phase that is an aqueous phase, and that the dispersed droplets are diversified, such as oil droplets, water-in-oil dispersion or water droplets, oil-in-water dispersion, etc. Therefore, in the external preparation for skin of the present invention, the dispersion droplet diversification type is particularly preferable.
分散滴複合タイプの複合乳化剤形の皮膚外用剤は、連続相に予め調整しておいた水中油乳化組成物(連続相は油相)、或いは、油中水乳化組成物(連続相は水相)を攪拌下徐々に加え、しかる後に均質化すれば製造することが出来る。 Dispersed droplet composite type composite emulsifier type skin external preparation is an oil-in-water emulsion composition (continuous phase is oil phase) prepared in advance in a continuous phase, or a water-in-oil emulsion composition (continuous phase is aqueous phase). ) Is gradually added under stirring and then homogenized.
分散滴多様化タイプは、予め水中油乳化剤形乃至は油中水乳化剤形を作成しておき、これに油中水乳化組成物乃至は水中油乳化組成物を添加し均質化すれば製造することが出来る。 The dispersion droplet diversification type is prepared by preparing an oil-in-water emulsifier form or a water-in-oil emulsifier form in advance, and adding the water-in-oil emulsion composition or the oil-in-water emulsion composition to this and homogenizing it. I can do it.
本発明の皮膚外用剤では、分散液多様化タイプの複合乳化剤形であって、水相を連続相とし、ここに油滴と油中水乳化滴が混在して分散する剤形であることが好ましい。この様
な乳化剤形に於いて、本発明の皮膚外用剤の必須成分である水溶性共重合体の乳化滴安定化効果が特に著しく発揮されるからである。
The external preparation for skin of the present invention is a dispersion type diversified composite emulsifier type, in which the aqueous phase is a continuous phase, and oil droplets and water-in-oil emulsified droplets are mixed and dispersed therein. preferable. This is because, in such an emulsifier form, the emulsion droplet stabilizing effect of the water-soluble copolymer, which is an essential component of the external preparation for skin of the present invention, is particularly remarkably exhibited.
前記の分散滴多様化タイプの複合乳化剤形であって、水相を連続相とし、ここに油滴と油中水乳化滴が混在して分散する剤形の場合、必須成分である有機変性粘土鉱物は、連続相である水相に分散している油中水乳化滴中に含有することが好ましい。又、この場合、分散する油滴は、アルカリを含有する、予め水酸化レシチンを溶解させた水相に、脂肪酸を含む油相を加え、水中油乳化組成物を形成せしめ、これに有機変性粘土鉱物を含む油中水乳化組成物を加え、所望により均質化し調整することが好ましい。この様な形態を採用することにより、乳化滴、油滴と水相の界面が強化され乳化安定性が向上する。又、水相中に分散する油中水乳化滴は、経皮吸収性に優れるので、有効成分である前記必須成分はここに含有させることが好ましい。 An organically modified clay that is an essential component in the case of the above-mentioned composite emulsifier form of diversified dispersion droplet type, in which the aqueous phase is a continuous phase and oil droplets and water-in-oil emulsified droplets are mixed and dispersed therein The mineral is preferably contained in water-in-oil emulsified droplets dispersed in an aqueous phase that is a continuous phase. Also, in this case, the oil droplets to be dispersed are added to an aqueous phase containing an alkali and pre-dissolved lecithin hydroxide to add an oil phase containing a fatty acid to form an oil-in-water emulsion composition. It is preferable to add a water-in-oil emulsified composition containing minerals and to homogenize and adjust as desired. By adopting such a form, the emulsified droplets, the interface between the oil droplets and the aqueous phase are strengthened, and the emulsion stability is improved. Moreover, since the water-in-oil emulsified droplets dispersed in the aqueous phase are excellent in percutaneous absorbability, it is preferable that the essential component as an active ingredient is contained therein.
本発明の皮膚外用剤に於いては、前記成分以外に通常皮膚外用剤で使用される任意成分を含有することが出来る。この様な任意成分としては、例えば、マカデミアナッツ油、アボガド油、トウモロコシ油、オリ−ブ油、ナタネ油、ゴマ油、ヒマシ油、サフラワ−油、綿実油、ホホバ油、ヤシ油、パ−ム油、液状ラノリン、硬化ヤシ油、硬化油、モクロウ、硬化ヒマシ油、ミツロウ、キャンデリラロウ、カルナウバロウ、イボタロウ、ラノリン、還元ラノリン、硬質ラノリン、ホホバロウ等のオイル、ワックス類;流動パラフィン、スクワラン、プリスタン、オゾケライト、パラフィン、セレシン、ワセリン、マイクロクリスタリンワックス等の炭化水素類;オレイン酸、イソステアリン酸、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、ベヘン酸、ウンデシレン酸等の高級脂肪酸類;セチルアルコ−ル、ステアリルアルコ−ル、イソステアリルアルコ−ル、ベヘニルアルコ−ル、オクチルドデカノ−ル、ミリスチルアルコ−ル、セトステアリルアルコ−ル等の高級アルコール等;イソオクタン酸セチル、ミリスチン酸イソプロピル、イソステアリン酸ヘキシルデシル、アジピン酸ジイソプロピル、セバチン酸ジ−2−エチルヘキシル、乳酸セチル、リンゴ酸ジイソステアリル、ジ−2−エチルヘキサン酸エチレングリコ−ル、ジカプリン酸ネオペンチルグリコール、ジ−2−ヘプチルウンデカン酸グリセリン、トリ−2−エチルヘキサン酸グリセリン、トリ−2−エチルヘキサン酸トリメチロ−ルプロパン、トリイソステアリン酸トリメチロ−ルプロパン、テトラ−2−エチルヘキサン酸ペンタンエリトリット等の合成エステル油類;ジメチルポリシロキサン、メチルフェニルポリシロキサン、ジフェニルポリシロキサン等の鎖状ポリシロキサン;オクタメチルシクロテトラシロキサン、デカメチルシクロペンタシロキサン、ドデカメチルシクロヘキサンシロキサン等の環状ポリシロキサン;アミノ変性ポリシロキサン、ポリエ−テル変性ポリシロキサン、アルキル変性ポリシロキサン、フッ素変性ポリシロキサン等の変性ポリシロキサン等のシリコーン油等の油剤類;ラウリル硫酸カリウム、アルキル硫酸トリエタノ−ルアミンエ−テル等のアニオン界面活性剤類;塩化ステアリルトリメチルアンモニウム、塩化ベンザルコニウム、ラウリルアミンオキサイド等のカチオン界面活性剤類;イミダゾリン系両性界面活性剤(2−ココイル−2−イミダゾリニウムヒドロキサイド−1−カルボキシエチロキシ2ナトリウム塩等)、ベタイン系界面活性剤(アルキルベタイン、アミドベタイン、スルホベタイン等)、アシルメチルタウリン等の両性界面活性剤類;ソルビタン脂肪酸エステル類(ソルビタンモノステアレ−ト、セスキオレイン酸ソルビタン等)、グリセリン脂肪酸類(モノステアリン酸グリセリン等)、プロピレングリコール脂肪酸エステル類(モノステアリン酸プロピレングリコ−ル等)、硬化ヒマシ油誘導体、グリセリンアルキルエ−テル、POEソルビタン脂肪酸エステル類(POEソルビタンモノオレエ−ト、モノステアリン酸ポリオキエチレンソルビタン等)、POEソルビット脂肪酸エステル類(POE−ソルビットモノラウレ−ト等)、POEグリセリン脂肪酸エステル類(POE−グリセリンモノイソステアレ−ト等)、POE脂肪酸エステル類(ポリエチレングリコ−ルモノオレ−ト、POEジステアレ−ト等)、POEアルキルエ−テル類(POE2−オクチルドデシルエ−テル等)、POEアルキルフェニルエ−テル類(POEノニルフェ
ニルエ−テル等)、プルロニック型類、POE・POPアルキルエ−テル類(POE・POP2−デシルテトラデシルエ−テル等)、テトロニック類、POEヒマシ油・硬化ヒマシ油誘導体(POEヒマシ油、POE硬化ヒマシ油等)、ショ糖脂肪酸エステル、アルキルグルコシド等の非イオン界面活性剤類;ポリエチレングリコ−ル、グリセリン、1,3−ブチレングリコ−ル、エリスリト−ル、ソルビト−ル、キシリト−ル、マルチト−ル、プロピレングリコ−ル、ジプロピレングリコ−ル、ジグリセリン、イソプレングリコ−ル、1,2−ペンタンジオ−ル、2,4−ヘキサンジオ−ル、1,2−ヘキサンジオ−ル、1,2−オクタンジオ−ル等の多価アルコ−ル類;ピロリドンカルボン酸ナトリウム、乳酸、乳酸ナトリウム等の保湿成分類;表面を処理されていても良い、マイカ、タルク、カオリン、合成雲母、炭酸カルシウム、炭酸マグネシウム、無水ケイ酸(シリカ)、酸化アルミニウム、硫酸バリウム等の粉体類、;表面を処理されていても良い、ベンガラ、黄酸化鉄、黒酸化鉄、酸化コバルト、群青、紺青、酸化チタン、酸化亜鉛の無機顔料類;表面を処理されていても良い、雲母チタン、魚燐箔、オキシ塩化ビスマス等のパ−ル剤類;レ−キ化されていても良い赤色202号、赤色228号、赤色226号、黄色4号、青色404号、黄色5号、赤色505号、赤色230号、赤色223号、橙色201号、赤色213号、黄色204号、黄色203号、青色1号、緑色201号、紫色201号、赤色204号等の有機色素類;ポリエチレン末、ポリメタクリル酸メチル、ナイロン粉末、オルガノポリシロキサンエラストマ−等の有機粉体類;パラアミノ安息香酸系紫外線吸収剤;アントラニル酸系紫外線吸収剤;サリチル酸系紫外線吸収剤、;桂皮酸系紫外線吸収剤、;ベンゾフェノン系紫外線吸収剤;糖系紫外線吸収剤;2−(2’−ヒドロキシ−5’−t−オクチルフェニル)ベンゾトリアゾ−ル、4−メトキシ−4’−t−ブチルジベンゾ
イルメタン等の紫外線吸収剤類;エタノ−ル、イソプロパノ−ル等の低級アルコール類;ビタミンA又はその誘導体、ビタミンB6塩酸塩、ビタミンB6トリパルミテ−ト、ビタミンB6ジオクタノエ−ト、ビタミンB2又はその誘導体、ビタミンB12、ビタミンB15又はその誘導体等のビタミンB類;α−トコフェロ−ル、β−トコフェロ−ル、γ−トコフェロ−ル、ビタミンEアセテ−ト等のビタミンE類、ビタミンD類、ビタミンH、パントテン酸、パンテチン、ピロロキノリンキノン等のビタミン類等;フェノキシエタノ−ル等の抗菌剤;ヘクトライト等の粘土鉱物などが好ましく例示できる。
In the external preparation for skin of the present invention, optional components usually used in external preparations for skin can be contained in addition to the above components. Such optional ingredients include, for example, macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, palm oil, palm oil, liquid Lanolin, hydrogenated coconut oil, hydrogenated oil, molasses, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ibotarou, lanolin, reduced lanolin, hard lanolin, jojoba wax, oils, waxes; liquid paraffin, squalane, pristane, ozokerite, Hydrocarbons such as paraffin, ceresin, petrolatum, microcrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, undecylenic acid; cetyl alcohol, stearyl alcohol -Le, Isosteari Higher alcohols such as alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, cetostearyl alcohol; cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, sebacic acid Di-2-ethylhexyl, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, glycerin tri-2-ethylhexanoate Synthetic ester oils such as trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentane erythritol tetra-2-ethylhexanoate; dimethylpolysiloxane, methylphenylpoly Chain polysiloxanes such as Loxane and diphenylpolysiloxane; Cyclic polysiloxanes such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexanesiloxane; Amino-modified polysiloxane, polyether-modified polysiloxane, and alkyl-modified polysiloxane Oils such as silicone oils such as modified polysiloxanes such as fluorine-modified polysiloxanes; Anionic surfactants such as potassium lauryl sulfate and triethanolamine alkyl sulfate; stearyltrimethylammonium chloride, benzalkonium chloride, laurylamine Cationic surfactants such as oxides; imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc. ), Betaine surfactants (alkylbetaines, amidebetaines, sulfobetaines, etc.), and amphoteric surfactants such as acylmethyltaurine; sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin Fatty acids (such as glyceryl monostearate), propylene glycol fatty acid esters (such as propylene glycol monostearate), hydrogenated castor oil derivatives, glycerin alkyl ether, POE sorbitan fatty acid esters (POE sorbitan monooleate) , Polyoxyethylene sorbitan monostearate, etc.), POE sorbite fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid Steals (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE2-octyldodecyl ether, etc.), POE alkylphenyl ethers (POE nonylphenyl ether, etc.), Pluronic types, POE / POP alkyl ethers (POE / POP2-decyltetradecyl ether, etc.), Tetronics, POE castor oil / hardened castor oil derivatives (POE castor oil, POE hardened castor oil, etc.), Nonionic surfactants such as sugar fatty acid esters and alkyl glucosides; polyethylene glycol, glycerin, 1,3-butylene glycol, erythritol, sorbitol, xylitol, maltitol, propylene glycol , Dipropylene glycol, diglycerin, isoprene glyco , 1,2-pentanediol, 2,4-hexanediol, 1,2-hexanediol, 1,2-octanediol, and other polyhydric alcohols; sodium pyrrolidonecarboxylate, lactic acid, lactic acid Moisturizing ingredients such as sodium; powders such as mica, talc, kaolin, synthetic mica, calcium carbonate, magnesium carbonate, anhydrous silicic acid (silica), aluminum oxide, barium sulfate, etc., whose surface may be treated; Bengara, yellow iron oxide, black iron oxide, cobalt oxide, ultramarine, bitumen, titanium oxide, zinc oxide inorganic pigments that may be treated on the surface; titanium mica, fish phosphorus that may be treated on the surface Pale agents such as foil and bismuth oxychloride; red 202, red 228, red 226, yellow 4, blue 404, yellow 5 and red 5 which may be laked Organic pigments such as No. 05, Red No. 230, Red No. 223, Orange No. 201, Red No. 213, Yellow No. 204, Yellow No. 203, Blue No. 1, Green No. 201, Purple No. 201, Red No. 204; Organic powders such as polymethyl methacrylate, nylon powder, organopolysiloxane elastomer; paraaminobenzoic acid UV absorbers; anthranilic acid UV absorbers; salicylic acid UV absorbers; cinnamic acid UV absorbers; Benzophenone UV absorbers; sugar UV absorbers; UV absorption of 2- (2'-hydroxy-5'-t-octylphenyl) benzotriazole, 4-methoxy-4'-t-butyldibenzoylmethane, etc. Agents: lower alcohols such as ethanol and isopropanol; vitamin A or its derivatives, vitamin B6 hydrochloride, vitamin B6 Vitamin Bs such as lipalmitate, vitamin B6 dioctanoate, vitamin B2 or derivatives thereof, vitamin B12, vitamin B15 or derivatives thereof; α-tocopherol, β-tocopherol, γ-tocopherol, vitamin E Preferred examples include vitamin E such as acetate, vitamin D, vitamin H, pantothenic acid, panthetin, pyrroloquinoline quinone and the like; antibacterial agent such as phenoxyethanol; and clay mineral such as hectorite.
以下に、実施例を挙げて更に詳細に本発明について、説明を加える。 Hereinafter, the present invention will be described in more detail with reference to examples.
[実施例1]
下記に示す処方に従って、本発明の化粧料を製造した。即ち、イ、ロ、ハの成分をそれぞれ80℃に加温し、イに攪拌下徐々にロを加えて、一次乳化して水中油乳化物を形成させ、これに更にハの成分を攪拌下加えて、二次乳化をして水中油中水・水中油混在の分散滴多様化タイプの複合乳化剤形とした。これを攪拌冷却し、本発明の化粧料である化粧料1を得た。同様に操作して、YAC化合物を水に置換した比較例1、センブリ抽出物1を水に置換した比較例2、YAC化合物とセンブリ抽出物1とを水に置換した比較例3も同様に作成した。
[Example 1]
The cosmetic of the present invention was produced according to the formulation shown below. That is, each of the ingredients i, b, and c is heated to 80 ° C., and b is gradually added to a while stirring to form a primary emulsified oil-in-water emulsion. In addition, secondary emulsification was carried out to obtain a diversified dispersion diversification type composite emulsifier type in which oil-in-water / water-in-oil mixed. This was stirred and cooled to obtain
<評価1>
化粧料1、比較例1〜3について、くすみ改善効果として、目の下のクマの改善作用を検討した。即ち、パネラー1群4名、計16名を集め、標準白色板で調整した色彩色差計(「ミノルタCR400」)で、頬部と白色板との色差、目の下のクマの部分と白色板との色差を求め、これより頬部とクマの色差を算出した。その後に、1日朝晩2回サンプルをクマの部分に適量投与してもらい、この作業を6週間続け、しかる後に再度頬部とクマとの色差を計測、算出した。結果を表2に示す。これより、本発明の化粧料はクマなどのくすみの改善に有用であることがわかる。
<
About
<評価2>
1群4名のパネラーで半顔を化粧料1で、もう半顔を比較例3で1日2回、20日間処置してもらい、しかる後に、比較例3に対して化粧料1がくすみの改善に優れるか否かを応えてもらった。結果は4名とも化粧料1の方が優れるとの回答であり、評価1の評価が裏付けられた。
<
One group of 4 panelists treated half-face with cosmetic 1 and the other half-face with Comparative Example 3 twice a day for 20 days. I was asked whether it was excellent in improvement. As a result, all four respondents said that cosmetic 1 was superior, and the evaluation of
[実施例2]
化粧料1と同様に操作して、化粧料2を製造した。このものを比較例3と、評価2の方法で評価したところ、4名中3名は化粧料2の方が優れると回答したが、1名は差異が不明瞭と回答した。センブリ抽出物のグルタチオン産生促進作用がくすみ改善に係わっており、グルタチオン産生促進値が1.4以上であることが好ましいことが判る。
[Example 2]
The cosmetic 2 was produced in the same manner as the cosmetic 1. When this was evaluated by the method of Comparative Example 3 and
[実施例3]
実施例1と同様に、水中油単純乳化剤形の本発明の化粧料3を作成した。このものを比較例3と、評価2の方法で評価したところ、4名中3名は化粧料3の方が優れると回答したが、1名は差異が不明瞭と回答した。複合乳化剤形における、油中水乳化滴への配合効果が確認された。
[Example 3]
In the same manner as in Example 1, a
本発明は化粧料などの皮膚外用剤に応用できる。 The present invention can be applied to skin external preparations such as cosmetics.
Claims (3)
1)リンドウ科センブリ属の植物体の抽出物と、2)前記YAC化合物及び/又はその塩とを組み合わせて配合するステップを含む、皮膚外用剤の製造方法であって、前記皮膚外用剤における、前記YAC化合物及び/又はその塩の含有量が皮膚外用剤全体の10 −4 〜10 −2 質量%である、方法。
<YAC化合物の特性>
(1)λmaxを405〜415nmと、660〜670nmとに有する。
(2)図1に示す1H−NMRスペクトルを有する。
(3)図2に示す13C−NMRスペクトルを有する。
(4)以下の条件でのHPLC分析において、15分前後にシングルピークを示す。
移動相:90%アセトニトリル
カラム:ODS4.6×250mm
流速:1ml/min.
温度:40℃
検知:紫外部210nm
(5)化学組成式はC34H40O9であり、質量分析スペクトルは593(M+H) Confirming that the YAC compound and / or salt thereof has the following properties; and
1) and extract of a plant of gentianaceae swertia, 2) a step of blending the YAC compound and / or a combination of a salt thereof, a process for the preparation of a skin external agent, in the external preparation for skin, The method whose content of the said YAC compound and / or its salt is 10 < -4 > -10-2 mass% of the whole skin external preparation .
<Characteristics of YAC compound>
(1) It has (lambda) max in 405-415 nm and 660-670 nm.
(2) It has the 1 H-NMR spectrum shown in FIG.
(3) It has a 13 C-NMR spectrum shown in FIG.
(4) In HPLC analysis under the following conditions, a single peak is shown around 15 minutes.
Mobile phase: 90% acetonitrile column: ODS 4.6 × 250 mm
Flow rate: 1 ml / min.
Temperature: 40 ° C
Detection: UV part 210nm
(5) The chemical composition formula is C 34 H 40 O 9 and the mass spectrometry spectrum is 593 (M + H).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013247525A JP5766775B2 (en) | 2013-11-29 | 2013-11-29 | Method for producing skin external preparation suitable for dullness improvement |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013247525A JP5766775B2 (en) | 2013-11-29 | 2013-11-29 | Method for producing skin external preparation suitable for dullness improvement |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008318858A Division JP2010138155A (en) | 2008-12-15 | 2008-12-15 | External preparation for skin suitable for ameliorating drabness |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014058552A JP2014058552A (en) | 2014-04-03 |
JP5766775B2 true JP5766775B2 (en) | 2015-08-19 |
Family
ID=50615343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013247525A Active JP5766775B2 (en) | 2013-11-29 | 2013-11-29 | Method for producing skin external preparation suitable for dullness improvement |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5766775B2 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003104835A (en) * | 2001-09-28 | 2003-04-09 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
JP2004026740A (en) * | 2002-06-27 | 2004-01-29 | Naris Cosmetics Co Ltd | Cosmetic |
JP2004035440A (en) * | 2002-07-02 | 2004-02-05 | Ichimaru Pharcos Co Ltd | Drabness inhibitor and external preparation for improving skin |
JP2007161663A (en) * | 2005-12-15 | 2007-06-28 | Pola Chem Ind Inc | Ages-decomposing cosmetic |
JP2008074721A (en) * | 2006-09-19 | 2008-04-03 | Noevir Co Ltd | Glutathione production promoter |
JP5424600B2 (en) * | 2008-09-16 | 2014-02-26 | ポーラ化成工業株式会社 | Advanced glycation end product degrading agent and cosmetics comprising the advanced glycation end product degrading agent |
-
2013
- 2013-11-29 JP JP2013247525A patent/JP5766775B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014058552A (en) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007161663A (en) | Ages-decomposing cosmetic | |
JP2010138154A (en) | External preparation for skin for dealing with aging | |
JP2007161663A5 (en) | ||
JP2008019230A5 (en) | ||
JP5424600B2 (en) | Advanced glycation end product degrading agent and cosmetics comprising the advanced glycation end product degrading agent | |
JP2007161660A5 (en) | ||
JP2007161660A (en) | Cosmetic for decomposing advanced glycation endproducts and method for producing the same | |
JP2007161662A5 (en) | ||
JP2010138153A (en) | External preparation for skin for ultraviolet prevention | |
JP2007161662A (en) | Cosmetic for decomposing advanced glycation endproducts | |
JP5766775B2 (en) | Method for producing skin external preparation suitable for dullness improvement | |
JP2010030935A (en) | Skin care preparation for external use | |
JP2007161661A (en) | Cosmetic for decomposing advanced glycation endproducts and method for producing the same | |
JP2007161661A5 (en) | ||
JP2008094734A (en) | Antiwrinkle agent and external preparation for skin | |
JP6249598B2 (en) | Topical skin preparation | |
JP5000964B2 (en) | Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression | |
JP4136997B2 (en) | Skin preparation for summer | |
JP2011246354A (en) | Skin external preparation | |
JP2010030933A (en) | Skin care preparation for external use | |
JP2010037245A (en) | Composition suitable for metabolic activation | |
JP2010138155A (en) | External preparation for skin suitable for ameliorating drabness | |
JP2005325076A (en) | Skin care preparation for external use having anti-inflammatory action | |
JP5768114B2 (en) | Method for producing an external preparation for aging | |
JP4404352B2 (en) | Skin preparation for summer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131220 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131220 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150602 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150617 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5766775 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |